E. Gasal

H. Groen, D. Planchard, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

D. Schadendorf, K. Flaherty, P. Ascierto, 2020 .

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dirk Schadendorf, Axel Hauschild, Antoni Ribas, 2019, European journal of cancer.

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020 .

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, Journal of Clinical Oncology.

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.

R. Dummer, J. Larkin, G. Long, 2018 .

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

K. Flaherty, Douglas B. Johnson, S. Patel, 2017 .

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Z. Wainberg, F. Ravandi, S. Dietrich, 2022, Blood.

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM).

D. Schadendorf, P. Ascierto, A. Boran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

A. Hauschild, D. Schadendorf, K. Flaherty, 2020 .

Pharmacovigilance in practice: erythropoiesis-stimulating agents

H. Ludwig, M. Hedenus, D. Henry, 2014, Cancer medicine.

Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.

B. Geoerger, J. Whitlock, C. Moertel, 2020 .

Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i

D. Schadendorf, P. Ascierto, R. Dummer, 2018, Clinical Trials.

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

V. Moreno, E. Muñoz-Couselo, N. Nebot, 2021, Clinical pharmacology in drug development.

561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours

J. Desai, G. Shapiro, A. Boran, 2020 .

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

J. Blay, P. Wen, M. Campone, 2021, Clinical Trials.